Cognition Therapeutics (NASDAQ:CGTX - Get Free Report) was upgraded by research analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a research note issued on Friday.
Several other research analysts have also recently weighed in on the stock. HC Wainwright restated a "buy" rating and set a $3.00 price target on shares of Cognition Therapeutics in a report on Thursday, June 26th. Chardan Capital reiterated a "buy" rating and issued a $4.00 target price on shares of Cognition Therapeutics in a research note on Friday, August 8th. One investment analyst has rated the stock with a Strong Buy rating and three have issued a Buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $2.83.
Read Our Latest Research Report on Cognition Therapeutics
Cognition Therapeutics Price Performance
Shares of NASDAQ:CGTX traded down $0.15 during midday trading on Friday, hitting $2.36. 3,199,914 shares of the company's stock were exchanged, compared to its average volume of 9,226,191. Cognition Therapeutics has a 12 month low of $0.22 and a 12 month high of $3.83. The company has a market cap of $173.51 million, a PE ratio of -3.52 and a beta of 1.33. The stock has a 50 day moving average price of $1.40 and a 200-day moving average price of $0.72.
Cognition Therapeutics (NASDAQ:CGTX - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.12) by $0.01. On average, analysts anticipate that Cognition Therapeutics will post -0.8 EPS for the current fiscal year.
Institutional Trading of Cognition Therapeutics
Hedge funds and other institutional investors have recently bought and sold shares of the company. Two Sigma Investments LP increased its holdings in Cognition Therapeutics by 372.2% during the 4th quarter. Two Sigma Investments LP now owns 53,691 shares of the company's stock worth $38,000 after acquiring an additional 42,321 shares during the period. Northeast Financial Consultants Inc increased its holdings in shares of Cognition Therapeutics by 158.6% in the 1st quarter. Northeast Financial Consultants Inc now owns 63,351 shares of the company's stock worth $27,000 after buying an additional 38,851 shares during the last quarter. CM Management LLC increased its holdings in shares of Cognition Therapeutics by 100.0% in the 1st quarter. CM Management LLC now owns 400,000 shares of the company's stock worth $168,000 after buying an additional 200,000 shares during the last quarter. Finally, Acadian Asset Management LLC increased its holdings in shares of Cognition Therapeutics by 814.1% in the 1st quarter. Acadian Asset Management LLC now owns 1,007,586 shares of the company's stock worth $422,000 after buying an additional 897,353 shares during the last quarter. Institutional investors own 43.35% of the company's stock.
Cognition Therapeutics Company Profile
(
Get Free Report)
Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.
Read More
Before you consider Cognition Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cognition Therapeutics wasn't on the list.
While Cognition Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.